Professor Page is a senior advisor to the Company. He is Professor of Pharmacology at King’s College, London and the work of his research team led to the establishment of the Sackler Institute of Pulmonary Pharmacology in 1993.
Professor Page is a fellow of the British Pharmacological Society and the Royal Society of Biology . He is internationally recognised for his work on asthma and on other lung diseases. He is also a member and former President of the Council of the Respiratory Section of the Royal Society of Medicine. His interests extend into the pharmacology of heparin and related GAGs, in particular the non-anti-coagulant activities of these molecules.
He has more than 250 papers published by peer reviewed journals; and contributed to over 30 books, ranging from Proceedings of International Meetings to chapters in textbooks of Pharmacology and Respiratory Medicine.
Recently Professor Page edited the first volume on the Pharmacology of Asthma and C.O.P.D. to appear in the prestigious “Handbook of Experimental Pharmacology” series and he is the Editor of a Textbook of Pharmacology, now in its 3rd Edition.
Professor Page is also the co-founder and former Chairman of the Board of Verona Pharma plc, which was listed in AIM in September 2006. He was a non-executive director of Cardiome Pharma (formerly Nortran Pharmaceuticals) in Vancouver, Canada from 1997 to 2002 and is currently a Non Executive Director of EpiEndo, PreP Biopharm and Babraham Biology Ltd, as well as a Trustee of the Babraham Institute.
Professor Page was awarded an OBE for “Services to Pharmacology” in the recent Queen’s Birthday Honours List.